201
© Springer Nature Singapore Pte Ltd. 2017
S. Sugathan et al. (eds.), Bioresources and Bioprocess in Biotechnology,
DOI 10.1007/978-981-10-4284-3_9
C.S. Sharanya • M. Haridas (*)
Inter University Centre for Bioscience, Department of Biotechnology and Microbiology,
Kannur University, Thalassery Campus, Kannur, Kerala 670661, India
e-mail: mharidasm@rediffmail.com
9
Anti-inflammatory Molecules: Enzyme
Inhibitors
C.S. Sharanya and Madathilkovilakath Haridas
Abstract
Structure/receptor-based drug design, a new approach of drug discovery, has
become a fascinating area of drug discovery/development. This rational approach
of drug discovery may lead to the production of many drugs, and some products
developed based on this approach are presently available in the market. Examples
of some of these drugs include saquinavir for the treatment of AIDS, captopril
against hypertension, dorzolamide for glaucoma and Zanamivir against influenza. Many molecules are designed based on their structure or receptors and are
under different stages of clinical trials. For applying rational approach, we have
to first identify the pathway of pathogenesis and the target proteins related to the
specific disease. After the identification of the specific protein, the compound
which inhibits the target protein may be designed to fit into the binding site of the
protein most appropriately. Compounds from natural sources are tested first, taking cues from various kinds of information. Such compounds may form a basic
structure which could be appropriated to the binding site of the target protein.
This chapter has been devoted to the inhibitors of the enzymes in the arachidonic
acid pathway which may serve as anti-inflammatory compounds. Target enzymes
of inflammatory pathway include isozymes of phospholipase A 2 (PLA 2 ), cyclooxygenase (COX) and lipoxygenase (LOX).
Keywords
Inflammation • Phospholipase A 2 inhibitors • Cyclooxygenase inhibitors •
Lipoxygenase inhibitors
© Springer Nature Singapore Pte Ltd. 2017
S. Sugathan et al. (eds.), Bioresources and Bioprocess in Biotechnology,
DOI 10.1007/978-981-10-4284-3_9
C.S. Sharanya • M. Haridas (*)
Inter University Centre for Bioscience, Department of Biotechnology and Microbiology,
Kannur University, Thalassery Campus, Kannur, Kerala 670661, India
e-mail: mharidasm@rediffmail.com
9
Anti-inflammatory Molecules: Enzyme
Inhibitors
C.S. Sharanya and Madathilkovilakath Haridas
Abstract
Structure/receptor-based drug design, a new approach of drug discovery, has
become a fascinating area of drug discovery/development. This rational approach
of drug discovery may lead to the production of many drugs, and some products
developed based on this approach are presently available in the market. Examples
of some of these drugs include saquinavir for the treatment of AIDS, captopril
against hypertension, dorzolamide for glaucoma and Zanamivir against influenza. Many molecules are designed based on their structure or receptors and are
under different stages of clinical trials. For applying rational approach, we have
to first identify the pathway of pathogenesis and the target proteins related to the
specific disease. After the identification of the specific protein, the compound
which inhibits the target protein may be designed to fit into the binding site of the
protein most appropriately. Compounds from natural sources are tested first, taking cues from various kinds of information. Such compounds may form a basic
structure which could be appropriated to the binding site of the target protein.
This chapter has been devoted to the inhibitors of the enzymes in the arachidonic
acid pathway which may serve as anti-inflammatory compounds. Target enzymes
of inflammatory pathway include isozymes of phospholipase A 2 (PLA 2 ), cyclooxygenase (COX) and lipoxygenase (LOX).
Keywords
Inflammation • Phospholipase A 2 inhibitors • Cyclooxygenase inhibitors •
Lipoxygenase inhibitors